Hydrogen Water Tablets
One of our core values is a genuine commitment to the honest pursuit of truth—a principle that guides every team member and everything we do. We reject the complacency of the status quo, where research is often controlled, filtered, or silenced, and instead champion transparency, integrity, and scientific curiosity.
We do not withhold the ability to publish research if we do not like the results. This sounds like a “no brainer”, however, this is not standard. In almost all industries, private companies that have funded research retain rights to be able to block publication of work on their products, if their results are unfavourable.
We believe this is unethical and goes against the pursuit of knowledge. If a trial doesn’t work, we intend to treat it as a “learning lesson” and refine our research in areas more likely to succeed; to date, all trials conducted on our molecular hydrogen tablets have found a favorable result! If a trial fails to find a benefit (and one eventually will), we are prepared to acknowledge and learn from it.
We do not demand strict control over the trial design. We do work with public researchers to advise on dosing and administration of our technology, and to provide insights into the research. We also will routinely connect researchers to other experts in the field, to help them gain insight into an area outside their own expertise.
No single researcher will possess all the needed knowledge and insight in order to design an effective trial. We work with researchers to design the best protocol to explore meaningful benefits and results; not to design protocols to “find some significant result” to market, with dubious clinical or real-world applicability. In the end, the public scientists have the final say on study design.
Our research philosophy has led us to an overwhelming pace regarding publications. Since reaching out to public teams, our tablet technology has been used in 10 clinical trials, 4 case studies, 3 preclinical publications, and an additional 16 clinical trials and 3 preclinical research programs are underway at various stages. None of this would be possible without the high levels of interest and passion from researchers, and we are dedicated to doing what we can to assist.